Key points from article :
Anastrozole is given as an adjuvant therapy for postmenopausal women after breast cancer surgery.
It works by stopping peripheral production of estrogen after menopause.
Reduced the risk of recurrence of breast cancer by 50% during the five years women took the drug.
49% fewer breast cancers, even seven years after stopping anastrozole, so the benefits lasted.
Analysed trial results of 3,864 women treated for breast cancers.
Collaborative research by multiple institutes, published in the Lancet.
